žÞ

Ɖīř1śřƎ¾-!+Virchow1 3 Ǝ¾#/D( 1ǏƉļ1ͧ2ǏƉŮÌ1

ùŊͧ3ǏƉĽÿ1Í§ď» B+AǎǏ¨Õ,1AfśŎĝ02

B?Virchow13

Ǝ¾1({0)Ɖ-ƉĽùŊ1ͧÐƸx!+A-ž?B+Aǎ33Ǐ`\0AAf0>AƉīïÿ2B7,2cHdnq-ƞ Ɖŏ0Ý9ƞƆƉīD=AƾƁƉī-ƔDB+&ŎÃ,2ƉßĦ¥D)

&Ŀ¶Ɖī,A-ž?B+Aǎ89Ǐ!!ĢÚlj,1AfśŎ30ò1õā Ɖ1AR-PL1­Ė0+OTŢź!&-?Af0AƉīïÿ02Ɖ ßĦ-›ÁŰŠ|0ˆœ!¶-,Ɖīïÿƨ B+-Ŧº B&

PT 2Î¾Ű›ÁųƟ-™ƦųƟAPTT 2š¾Ű›ÁųƟ-™ƦųƟ0A¾Ó ĻùE®Ĝ#A&:0SMns^qNĭĩ,œ?B+Aǎ1519ǏĢţũ,2 yż0AõāƉ1PTAPTT1-;0ğû/ͧ2Ɯ:?B/)&7&

D-dimer2×Ù§cHdnqemSiq0>)+Ɠ BA-,ő"AƓŒň

,@1Afúſ0AD-dimer1uĚ2ƉīïÿEŤƜ#A&:0ğœ,

A-ž?B+Aǎ7779ǏAT2ƉĽz,›ÁƹÛ¾Ó-!+›Á®÷E¡

ó#AőŐŜTnqepZGsUIq`aVs,A%1&:ATĻù1†v2 ƉīïÿEŦº#A;1,A- B+Aǎ90, 91ǏĢţũ0+õāš1

D-dimer/?40ATĻù0ğû/ŶĝŜͧƜ:?B/)&«¾-!+T-TAS

1ŴĨ?õāš1›Á¾Ó1Ļù§-ƉĽùŊ1ͧ2ő"A;1130  -ŢĠƷ,2ؘ/AƉīïÿ02Ƅ)+/)&;1-ž?BA

7&¨Õ,1Ɖīïÿ1VIiqN0Ƹ!+22 ĘƷu1 Af ĉŷ!&ř

Š15−14Ǎ0+>4ĉŷùAfúſ129Ǎ0+0Ɖīïÿ BA-ƔD B+@ǎ64, 87ǏAfő"&12ĝƷš0ƉßĦ-›Á¾Ó1ĻùƶÒ BA

96 -ɹ B+Aǎ87Ǐ!!Ģţũ,2T-TASEŁÙ!&ŴĨNJdžèõā

¢ńòD$30 -ŢĝƷ,õāš0+ƉßĦİƀ-›Áƀ1}ƨő

"A-ě?-/)&7&Pq\psoż1õāƉ>4ġĬƉ,2$B 0+;ğûâƜ:?/)&-?Ɖīïÿ•¸2fsRqN0>A;1, A-ě?-/)&&'!30 -ŢĝƷ,2õāš0AƉī2 ŤƜœĤ+/-?Ɖīïÿ07,2Ƅ)+/-ž?BA ĀšAƺ@B7,AfśŎşò1õāš-ġĬƯ…0AƉĽùŊ1ͧ

EĵƢ!&ɹ2Ɯ:?B+/€½õāš0+18¤Ŝ/ƉĽùŊ1ͧ

ƒÞ B&ġĬƯ…,2$B1ĭĩǂŞ0+;ğû/ŶĝŜͧ2Ɯ:?

B/)&1ŐŔ-!+ġĬƯ…,2ƉĽ1ľ8à/-<Ų¦-ň ŐŜ/¢ń0>AƉٚŝƽÛà/-/.ĎŁ BAu1ŴĨ?`\

1AFŊü,;·Į0ġĬƉ,1›ÁŖäƜ:?B/ʶ,;õāš,1›Á }ƨŊü0ƻ)+A²ƀùíŦº BA

Ģţũ0+ƉĽ›ÁƀǎƉīïÿƀǏ1}ƨE;&?!&«¾-!+Ų¦

0>Aijä/õā¯źÑDB&-0>AƉĽ1)Ń<õāšƂ1”Û1ÔÃ ĎŁ BAĢÚlj,‰œ!&AR-PL2ƉßĦĒ0ðǁ B/-ƔDB+A ǎ20ǏĢÚlj,2B?1Ž0Ƹ!+1ĭƖ2Ɗ)+/&:%1ƓƱ02

©0Ĺû#AöƎA-ž?BAĢţũ,1‹ƛ¦ň2k[oˆÿĝ02’

ä*ƇnjÁ‡,)&Guidelines for Pharmacotherapy of Atrial FibrillationǎJCS 2013Ǐ ,3žśùAf0Šî#Aǎ83Ǐ%1&:Af1Èť-/Aõā1ŘŐÕŜͧ

ơè,A-ž?BAƃçŎÊ,ƭƪ#AAfúſ,2ćìÅõŭřýùê ƂřõāzƼıđř–åêŋŪř/.õŗúƨƊ!&Ŋü,Ɯ:?BA-š

?B+A&:õŗú0„õŭƽÛÔÃ#A-?;Ģţũ1ŴĨ-ĵƢ!

+õāš1ƉĽùŊ1ͧ>@¤Ŝ,A²ƀùA

97

ßĈ

Ŭ 3 ū1ýùĠÚlj,2õā0NJdžèõā¢ńEx& Af k[oʼn0+

T-TASEœA-0>@AfśŎò1 ƧƷò02õāš0+Ɖīïÿ-/AƉ ĽùŊ1ͧő"ǐ%B ƧƷĉŷ#A-ě?-/)&!!/?

Af1śŎò1øùĠ0+.1VIiqN,õāšA2ġĬƯ…0+

ƉĽùŊ1ͧő"A2ŎÃ1-Cě?0/)+/

Ģţũ,2T-TASEœA-0>@AfśŎ -ŢĝƷ,õāƉš0 +ƉßĦİƀ-›Áƀ1}ƨő"A-ě?-/)&

ʼn0+Af 1øùĠ1õāƉ1ƉĽùŊ1ͧEƝ5&ɹ2Ģţũž:+,

@ŢĝƷ,Ɖī•¸•¸Ɯ:?B&-2ƃçŎÊ0+AfƜ:?B&

ʶ02>@ęĠ0ąƉīŚĸEƶÒ!&6ƅ-ĕ&/ķŚĖƳEďŦ,

&²ƀùNJ

98

6. LŒ

L3-f. Xž3;-'=: Xž€0=%:16›8›B ”?_Tˆ4=)7=$=9=. P‘!¡4=(<%…¢u8›4 =(<% ŠF|G^f‰ Xg¡'<-;=:…¢4=(<%…d‹]™ †b10h—‹^ m— Ž^_cŸœ\F|GF|–U30D^Jj~?dwT-TASrp‰yCMt‡r p‰yrp Xg

99

0 100

200

300

400 Pre 30 min Pacing Control

(sec) L3-g 4=(<%…'<-;=:…_c‰AR+,3OT JzW@[O@± s{AZŒ*£4=(<%…F|Gvp<0.05laZ Pacing£4=(<% Xg… (390 bpm, 2mV, n=8)Control£4=(<% Xg …(n=8)Pre£Ÿœ\_cF|G30 min£ Ÿœ\_cF|30D^ AR£‰Yot‡CMt‡ zW+,3OT£•Rj—

*

100

L3-h. 4=(<%…'<-;=:…_c‰PL+,3OT JzW@[O@± s{AZŒ*£4=(<%…F|Gvp<0.05laZ Pacing£4=(<% Xg… (390 bpm, 2 mV, n=8)Control£4=(<% Š …(n=8)Pre£Ÿœ\_cF|G30 min£ Ÿœ\_cF|30D^ PL£‰Yot‡ zW+,3OT£•Rj—

0 100

200

300

400 Pre 30 min Pacing Control

*

(sec)

101

L3-i. 4=(<%…'<-;=:…nq‰AR+,3OT JzW@[O@± s{AZŒPacing£4=(<% Xg… (390 bpm, 2 mV, n=8)Control£4=(<% Xg …(n=8)Pre£Ÿœ\_cF|G30 min£Ÿœ\_cF|30D^ AR£‰Yot‡CMt‡ zW+,3OT£•Rj —

0 100

200

300

400 Pre 30 min

(sec)

Pacing Control

102

L3-j. 4=(<%…'<-;=:…nq‰PL+,3OT JzW@[O@± s{AZŒPacing£4=(<% Xg… (390 bpm, 2 mV, n=8)Control£4=(<% Xg …(n=8)Pre£Ÿœ\_cF|G30 min£Ÿœ\_cF|30D^ PL£‰Yot‡ zW+,3OT£•Rj—

0 100

200

300

400 Pre 30 min

(sec) Pacing Control

103

Œ3-f. '<-;=:…4=(<%…_c‰T-TAS@SH JzW@[O@± s{AZŒ*£F|Gvp<0.05laZ'<-;=:…£4=(<% Xg …(n=8)4=(<%…£4=(<% Xg… (390 bpm, 2 mV, n=8)Pre£Ÿœ\_cF|G30 min£Ÿœ\_cF|30D^ AR,chip£CMƒ‰Yot‡ zW+,3PL, chip£‰Yot‡ zW+,3 T10£•R–Uj— OT£•Rj—AR +,3+80 kPa PL+,3+60 kPaE’j—AUC£N>ik„?“šQ˜‚

104

Œ3-g. '<-;=:…4=(<%…nq‰T-TAS@SH JzW@[O@± s{AZŒ'<-;=:…£4=(<% Xg …(n=8)4=(<%…£4=(<% Xg … (390 bpm, 2 mV, n=8)Pre£Ÿœ\_cF|G30 min£Ÿœ\_cF|30D^AR,chip£CMƒ‰Yot‡ zW+ ,3PL, chip£‰Yot‡ zW+,3 T10£•R–Uj— OT£•Rj—AR+,3+80 kPa PL+,3+60 kPa E’j—AUC£N>ik„?“šQ˜‚

105

Œ3-h. '<-;=:…4=(<%…_c‰‰yCM@SH JzW@[O@± s{AZŒ'<-;=:…£4=(<% Xg …(n=8)4=(<%…£4=(<% Xg … (390 bpm, 2 mV, n=8)Pre£Ÿœ\_cF|G30 min£Ÿœ\_cF|30D^PT£3;-;<0<j—(I†@, 7.4–8.8 s) APTT£x`H“D-;<538)+<j—(I†@, 12.0–28.8 s)Fibn : 1"29/=&<}\(I†@, 150–350 mg/dl)D-dimer£D- *#6= (I†@ < 2.0 μg/dl)AT£eCMKV (I†@, 102–156 %)

67

ƽ3Ƽ ɋɅğįĽÉƍƓJƝ.ǭƂ¿êǝ:Ȃ¨

ɐ - ĹIJşɏ Af Ȯÿ 1, 2, 3 ȘȯĨɐ9$GǭƂ¿êǝ:Ȃ¨ –

68

11. ǒǺ

–Ðƥ94įÓIJǟõū:Óç:0ȾġǡIJįĽljÎɏnon valvular Atrial

fibrillation: NVAFɐ ÒAGËÜ;45Ɏ6ŝBû#ü!8Ȱį ž H4Gɏ3, 63

65ɐŒŒƕÐƥ94įĽljÎɏAfɐ9DGǭūõūƤ:óà;Đ8#ɏ13, 14ɐ Š/Ưƺ ÑÂ5G

ƽ2Ƽ:Ưƺ5;—æ¥Ɲ'.Af€k…Ɠ94įĽŵǝ:¢ŽCįĽŅü 9DFįĽ¼941ǭ ƛ(G%6 ÄŘ'.Afś9;’9ĕįǛ9ǭ ū ƛ(G%6 ƬEH4G %H;ĕĽ¼:1ǭ9DGǭƂIJƔ:ùσ 9¿êDž:ſIJ ƛ(G%69Ȋç)G%6 óà&H4Gɏ6, 7ɐ¿êçĀ:Œ2 5GƽçĀ;ǭƀȖğ:țĕįǛ875ſIJÏ)G%6 ƬEH4Gɏ66ɐ

?.–:Afijǚ:0)59ǭūƛĻ ȄAEH4GB:5;šŮǭ9$

GuNv„p‹[ˆƏğ (Fibn : Fibrinogen ) CƽçĀ87:¿êçĀ|‹U‹:ɋ

­Ï óà&H4Gɏ63, 6770ɐ%:D9ǭƂ:1Ƌ ƛ(GĕĽ¼5;¿

êçĀ:ſIJÏ9DFuNv„ˆJ’6'.ǭū ĦĻ&HG%6 ƬEH4G ''Ćȳ:Afijǚ9$GįĽ¼9$GǭƂIJƔ:ǎśƨùÏJóà'.B:

;ȄAEH8?.Ɠ:Af9Ȱ'4;–6Ýű9Af Óç6ǙEHGǭū õūƤ óà&H4GB::ɏ13, 14ɐAfƦƗś9$GǭūĦĻ:fO}ˆYC ǭūIJƔ9Ȱ)GĴó;8#ŘE9&H48

ȒĝºǭǭūĦĻǸƈ_aj~ɏTotal Thrombus-formation Analysis SystemɕT-TASɐ 6ǭūŶǭůũŵå DFƛ£¼9ȒǭƀŽ5:ǭďŦŵǝ6¿êçĀŵǝJ ƈą)G%6Jƪƨ6'4ÐƥƝ9ȮƦ&Hɏ2022ɐƓ94B,:ǤĞıƝ :óà ȄAEH4Gɏ29ɐŢƯƺ;ĪŤE:w‡l‡ˆsˆśȯɏPTɐſ IJÏȡÂl‡ˆzwƒahˆśȯ (APTT)uNv„p‹[ˆƏğɏFibnɐD-gO|‹

ɏD-dimerɐŁ¿êçĀɏATɐ87:ǭƂ¿êůũ6T-TAS JƝ4ĆɊƨ9

¤Ļ&H.Afś:Ɠ9$GįĽ¼D=šŮ9$GǭƂ¿êIJƔ:ǎśƨùÏJ ŹȎůǼ'ǭū„aXJʼnG%6Jƪƨ6'.

69

22. Œż

2-1. V O m ƒ O ˆ : ȟ ă

ŢƯƺ;ť•ȏĔüĂÎƑĆɊ®ƙǵą9Ɖń'ȚǮ'.ɏĿȄƟÚɕƽ Úɐ

2-2. § ȃ Î Ƒ

ƽ2Ƽ6Ýű9įǢ9äɆ 86Ȁő'.ĆɊƝs‹Y…Ɠ8ɃJ§ȃ'.IJ Å;ȵD=ȷ,H-H4Ƀ*2ĝɍ;1ɖ5Ÿɍɏ‘ý­ɕ 2Ÿɍɐ£Ȧ;9.0 ɖ12.5 kgɏ‘ý­ɕ10.8 kgɐ51.

2-3. Af€ k … Ɠ : ¤ Ļ

ƽ2Ƽ6Ýű:ŒżJƝ4s‹Y…Ɠ8Ƀ9ºȌɌȣŽ5įúǡy‹a‹U‹

„‹mJðAȑK/,:Ĩy‹a‹U‹„‹mJ£úĢÉƍDZǗ9ŋǏ'2 mV 390 bpm94ɋɅğįĽÉƍJǮ%HJAf€k…6'.

2-4. Ć Ɋ w ‡ l \ ‹ …

ƽ2Ƽ6Ýű:ŒżJƝ4ľǯ:ħɀJǙĺ'410ŕȯ:ǯĨƥɈşȯJǾ$

.,:ĨįĽɋɅğÉƍÊɏPreɐÉƍȮÿ1ȘĨɏ1wɐ2ȘĨɏ2wɐD=3 ȘĨɏ3wɐ:ÛśƐ94Žǽ:ľż9D14T-TASůũǭƂ¿êŵǝůũ ǭƂůũD=ǭëůũJĆœ'.ǭƂůũD=ǭëůũ;ÛśƐ94£

úĢÉƍDZǗ9DGÉƍJŒğ°Ŷ'4E30ÂNjȜĨ9Ǯ1.ɏé3-aɐ

2-5.ů ũ

2-5-1. Ŋ ǭ Œ ż

ǽ:Af€k…Ɠ9ɌȣÊŀǫ6'4ưȤMl‡tˆ0.05 mg/kg S.CȢƮ

70 Ȥvl…uLp‹…0.2 mg/kg I.V}geƒ~0.2 mg/kg I.VJŀ'.Ĩ9w‡{

uS‹…6 mg/kg I.V5Ď¹'Odu…ƒˆ5ɌȣǐŇJǮºȌɌȣŽ9.

Ù²Ŵǣ¡5ªą'ĕ²ɄȡƩǠJdž4 cmÃȮ'ɄȽǞJȼÁ'.,:Ĩ5 Fr :ŪɈUj‹j…ɏMl~ŪɈUj‹j…5 FrɕMl~kNU…ŬĢƴť•ɐ JɄȽǞJUilgPˆ)G%69DFň¹'XǓȔǶŽ5¡ǗJƱȄ'8 EÙ įĽ?5Uj‹j…JșA.Uj‹j…DFÙįĽ¼:ǭƂJŊ×'.B:JįĽ ǭ6'.ÝɌȣţ›Ž94ú²œìȽǞDF20 GǘƔȩJƝ4Ŋǭ'.B :JšŮǭ6'.

22-5-2. T-TAS 9 D G ƈ ą

T-TAS;ºǭJƝǭƀal†aāìŽ5ǭūĦĻJŏ­ƨŠǶǷƨ9Ȃ¨)G ǑÜƨůũ_aj~5G2Ƹɇ:čƝ|OX‡hiw āì'PLhiw;ǭď ŦŵǝJȂ¨)Ghiw5FARhiw;¿êǝD=ǭďŦŵǝJǑÜƨ9Ȃ¨

)Ghiw5GÛhiw:|OX‡ƀȋ9įĽǭG;šŮǭ:ºǭ^ˆw…J ƀ¹&+|OX‡ƀȋ¼9$GǭūĦĻ9DG¼ëŗJƈą'.¼ë òǓD F+10 kPa9Çȝ'.śƐJȭõȮÿśȯɏTime to 10 kPašŽT10ɐPLhiw5;

òǓDF+60 kPaARhiw5;+80 kPa:śƐJȭõśȯɏOcclusion TimešŽ

OTɐ6'4,HE:śȯD=ëŗŜǓ:ŽȡɂñȿƹɏArea Under the flow pressure CurvešŽAUCɐJǻƈ'.

2-5-3. ǭƂ¿êǝůũ 2-5-3-1. PTAPTTFibn

ǽ:T-TAS9Ɲ.ŊǭŒż9D14Ŋǭ'.įĽǭD=šŮǭJƝ

.ºǭ0.45ml93.2 ɎXRˆȤƊƂ0.05mlJƅÍ'.ǭƂJh‚‹v9ž' ďïĮȧȞįŵɏPMC-060ɕl}‹DŽĔť•ɐJƝ4ćƇ94ȞįÂȹɏ645

gŠ5 ÂȯɐJĆœ'ǭƌJī.Ĩƫ09w‡l‡ˆsˆśȯɏPTɐſIJÏȡÂl

71

‡ˆzwƒahˆśȯɏAPTTɐuNv„p‹[ˆƏğɏFibnɐJƈą'.ƈą9

;ǭƂ¿êÂŧDZǗɏWAKO Coag 2Vɕâ·LJǫĔŰŬĢƴť•ɐJ¥Ɲ'.

PT:ƈą9;PTŠAPTTƈąƝĘȥƂB 50μlɏâ·LJǫĔŰŬĢƴť•ɐ6

ǽ5īEH.XRˆȤÍǭƌ50μlJ¹HƄÜ'2¬Ęȥ:ǭƌJ¤Ļ'.,:Ĩ l‡ˆzwƒahˆȃǫU‹mɏP^WǟƞŤɐ:ȃŐň¹ȡ9Ęȥů£ 25μl Jƅ Í'ƈą'.APTT:ƈą9;PTÝűPTŠAPTTƈąƝĘȥƂB 50μlɏâ·LJǫ ĔŰŬĢƴť•ɐ6ǽ5īEH.XRˆȤÍǭƌ 50μlJ¹HƄÜ'2 ¬Ęȥ:

ǭƌJ¤Ļ',:ĨſIJÏȡÂw‡l‡ˆsˆßŞȃǫU‹mɏP^WǟƞŤɐ:

ȃŐň¹ȡ9Ęȥů£ 25μlJƅÍ'ƈą'.Fibn :ƈą9;uNv„p‹[ˆ

ƈąƝĘȥƂB 350μlɏâ·LJǫĔŰŬĢƴť•ɐ6ǽ5īEH.XRˆȤÍǭ ƌ25μlJ¹HƄÜ'15¬Ęȥ:ǭƌJ¤Ļ'.,:ĨuNv„p‹[ˆȃǫU‹

mɏP_l‡ˆsˆɐ:ȃŐň¹ȡ9Ęȥů£ 25μl JƅÍ'ƈą'.,H-H:

ÔǙ­6'4;â·LJǫĔŰŬĢƴ5īEH.­ɏùΩŏɏCVɐ9Ȱ'4;

PTAPTTFibn,H-H9410%šŽ:ǂèŷƱIJ9Ȱ'4;PTAPTT ,H-H94ŔƬ¿êśȯ:10%š¼Fibn5;ŔƬƏğ:15%š¼ɐJƝ .

2-5-3-2. D-dimerAT

D-dimerD=AT:ƈą;ǽ:ȞįÂȹ'.XRˆȤǭƌJƫ09−80 9

½¾ªā'.B:JƝ.,H-H:ƈą;½¾ů£J?6A4ȶǪ'4BE ĊøuN…~€p„aŬĢƴ94šŽ:Œż94Ǯ1.

D-dimer;rluNv„ˆuƒYˆlD-dimerŁÓ9Č'4Ɯƛ&H.€pX‡‹

n…Ł£9ò3#¸ơĂƨľż5ůÁ&HGŢƯƺ5;ƒijXa¸ơŹƎż ɏLatex turbidimetric immunoassayɐɏĊøuN…~€p„aŬĢƴť•ɐJ¥Ɲ'.

ŁrlD- dimer|Pa€pX‡‹n…Ł£Jķ¤'.ƒijXaǃĀ9ů£JÕı&

+G6ů£‘:D-gO|‹6ŁrlD-dimer|Pa€pX‡‹n…Ł£ķ¤ƒjiXa

72 ŁÓŁ£ÕıJȊ%'ů£‘:D-dimerƏğ9Ź¦'4ƒijXaǃĀ ¿ȶ)G

%:¿ȶ:ĥ&JŽȬ500800nm94ƈą'D-dimerƏğJźA.ɏ71ɐ AT :ƈą9;ÜĻòȈżɏSynthetic substrate methodɐɏĊøuN…~€p„aŬ Ģƴť•ɐJ¥Ɲ'.AT ſIJ;ů£‘: AT ¤Ɲ&

+ATDzÜ£JĎ!&+.Ĩ%:ſIJÏ&H.AT

¤Ɲ&+G6DzÜ£:njÜ'þſ)G

ſIJJòȈ D-uQo…Mƒo…-w‡„…-M…Woˆ-4-Mbh…

Mƒom(NA-4100)JƝ4ƈą)G%69D14ů£‘: AT ſIJJźA.ƈą

ż;†‹lMibOż94Ǯ1.ɏ72ɐ

2-5-4. ĄºǭƘǻǀɏCBCɐ

EDTAŊǭǁ9ž'.ǭƂJD#ŎŃ'.ĨǑƧǭƘŏɏWBCɐȉǭƘŏɏRBCɐ x€Y‡sˆƏğɏHGBɐx|lX„il­ɏHCTɐĜîȉǭƘĉƹɏMCVɐĜ îȉǭƘǭǨLjŏɏMCHɐĜîȉǭƘǭǨLjƏğɏMCHCɐ,'4ǑǭďŦŏɏPLTɐ Jƈą'.ƈą9;ÎƑÞ$ºǥÎǭƘǻǀŵɏMEK-6450 b…fiXɕŕŢ·

Ȼť•ɐJ¥Ɲ'.

22-5-5. ǭ Ƃ Ï Ă ů ũ

xq„ˆh‚‹v9ž'.ǭƂJďïĮȧȞįŵɏPMC-060ɕl}‹DŽĔť

•ɐJƝ4ȞįÂȹɏ645gŠ5Âȯɐ'4ǭƌJī.ĨĒLjƻLjɏBUNɐX†

MhoˆɏCREɐY…f}ˆȤt…sˆȤlƒˆaM}ƒ‹cƏğɏGPTɐǑǬƧ ɏTPɐM…v}ˆɏALBɐ:ÛíJƈą'.,H-H:ƈą9;ÎƑƝǭƂÏĂ ŧDZǗɏĊømƒOZ~7000ɕĊøuN…~kNU…ť•ɐJ¥Ɲ'.

2-5-6. Ȼ ǹ Ȉ ů ũ

xq„ˆh‚‹v9ž'.ǭƂJďïĮȧȞįŵɏPMC-060ɕl}‹DŽĔť

73

•ɐJƝ4ćƇ94ȞįÂȹɏ645gŠ5ÂȯɐJĆœ'ǭƌJī.Ĩnl„P~

ɏNaɐU„P~ɏKɐX‡‹…ɏClɐJƈą'.ƈą9;OTˆȠłÈÂŧDZǗ ɏĊømƒOZ~800ɕĊøuN…~kNU…ť•ɐJ¥Ɲ'.

22-5-7. ǭ ë ů ũ

ǭëƈą;T_‡l„iXżJƈąÓƙ6'.ÎƑƝȾǸǭƨǭëǻ

ɏBP-100DɕFukuda ME Kogyo CO., Ltd., Tokyo, JapanɐJ¥Ɲ'.ƈąȡ¡;

đŭȡ6'Uuě;ƈąȡ¡áȐ:40ɖ60 %ě6'.ɏ ɐÖǕşÎǞëɏSAP ; systolic arterial blood pressureɐĜîÎǞëɏMAP ; mean arterial blood pressureɐD=

ŅĤşÎǞëɏDAP ; diastolic arterial blood pressureɐJɔæǻƈ',:Ĝî­JB1 4ƈą­6'.?.ÔǙ­;CoulterE:­JƝ.ɏ ɐPre1w2wD

=3w:ÛśƐ94£úĢÉƍDZǗ9DGÉƍJŒğ°Ŷ'30ÂNjȜĨ9ƈ ąJ%81.

2-5-8. Ǎ ǻ ǹ ŧ

ƈą­;Ĝî­ŲƉ¯Ė5Ƴ'.ÛśƐ9$Gǻƈ­ ŷǵÂė'4G7 JƱȄ)G.A:ŷǵƱƖw‡ilJ¤Ļ'_t‡ŠPN…XůąD=\…

€]‡uŠa}…puůąJƝ4Âė:ŷǵIJ:ůąJǮ1.

k‹f ŷǵÂė)GôÜ;One-way ANOVAJǮDunnet test9D14ûȦŹ ȎJǮ1.ŷǵÂė'8ôÜ9;Freedman’s testJǮWilcoxon signed-rank test with Bonferroni correction9D14ûȦŹȎJǮ1.p<0.05JǍǻĂƨŞĶ5G6Ä ő'.

3. njŨ

3-1ɒT-TASůũ

74 (a) įĽǭ

įĽǭ:ARhiw94OT 6T10;Pre6ŹȎ'41w2w3w94 ,H-HŞĶ9ƭǕ'.ɏ*HBp<0.05ɐAUC;Pre6ŹȎ'41w2w3w9 4,H-HŞĶ9öÍ'.ɏ*HBp<0.05ɐɏé3-bɐįĽǭ:PLhiw9 4OT;Pre6ŹȎ'4ÉƍĨ9ĩ9ƭǕ³ÞJƳ'3w9ŞĶ9ƭǕ'.ɏ

*HBp<0.05ɐT₁₀;Pre6ŹȎ'41w2w3w:º494ƭǕ³Þ;Ƴ'.

ŞĶ8ùÏ;@EH81.AUC;3w9ŞĶ9ŗ'.ɏp<0.05ɐɏé3-cɐ ɏǰ3-aɐ

(b)šŮǭ

šŮǭ94;ARhiwPLhiw»9º4:Ɂƪ5ŞĶ8ùÏ;@EH8 1.ɏé3-d, é3-eɐɏǰ3-aɐ

3-2. ǭƂ¿êŵůũ (a)įĽǭ

įĽǭ:APTT94Pre6ŹȎ'41w2w3w:,H-H94ŞĶ9 ĠȬ'. *HBÔǙ­:ǂè¼5:ùÏ51.PTFibnD-dimerAT :

™:Ɂƪ924;ÔǙ­ǂè¼JŌƶ'ŞĶ8ùÏ;ǴEH81.ɏÔǙ­

PTɕ7.4Ƶɖ8.8ƵAPTTɕ12.0ɖ28.8ƵFibɕ150ɖ350 mgD-dimerɕ2 μg/mlATɕ 102ɖ156 %ɐɏǰ3-bɐ

(b)šŮǭ

šŮǭ94;*H:Ɂƪ94BŞĶ8ùÏ;@EH81.ɏÔǙ­

PTɕ7.4Ƶɖ8.8ƵAPTTɕ12.0ɖ28.8ƵFibɕ150ɖ350 mgD-dimerɕ2 μg/mlATɕ 102ɖ156 %ɐɏǰ3-bɐ

75

3-3. ĄºǭƘǻǀɏCBCɐ

*H:Ɂƪ94BŞĶ8ùÏ;ƱȄ&H81.ɏǰ3-cɐ

3-4. ǭƂÏĂůũD=ȻǹȈůũ

*H:Ɂƪ94BŞĶ8ùÏ;ƱȄ&H81.ɏǰ3-dɐ

3-5. ǭëůũ

SAPMAPD=DAP*H94BPre6ŹȎ'41w2w3w94 ,H-HŞĶ9¢Ž'.ɏp<0.05ɐɏǰ3-eɐ

44. Ǚċ

ƽ Ƽ:Ưƺ9DFǭūƤ:ƦƤdzç6'4Virchow: dzç)8I0 ɐǭƀ :ùÏɐǭǁ÷:IJƔùÏD= ɐǭƂĻÂ:ùÏɏɐ:0ǭƀ:

ùÏ2?FįĽ¼9$G1ǭ ƛ(G%6 ŘE681.–:AfƦƗś9

;įĽ¼6#9ĕįǛ9$GǭƂ:1Ƌ6¿êDž:“ș9DFǭū ĦĻ&

H%6 ƬEH4Gɏ33ɐĆȳ–:Afijǚ:įR\‹ůũ94ĕįĽ¼9 BCBCR\‹´ɏSpontaneous echo contrast : SECɐ ƱȄ&HG%6 Gɏ75ɐ

%:SEC:Ţ£;ȉǭƘ6uNv„p‹[ˆJ˜'.ȗȪĦĻ5F%:D8 ǭƂIJƔ:ùÏ ǭūĦĻ9¶ɉ$4Ǹċ&HG%6 ûɏ76ɐŢƯƺ94;

€k…ÎƑ:1Ƀ9:@įĽ¼5SEC Ǹċ&H.%:Ƥ¦5;Éƍ3Șƪ9 4SEC Ǹċ&H,:įĽǭ:­;,H-HPL:OT 223ƵAR:OT

76 176Ƶ6™:«£6ŹȎ'4AR:ƭǕ ȄAEH.%:%6EBSEC; uNv„p[‹ˆJ’£6'.B::ØǝIJ ǙEH.

–:ĹIJ:Af ijǚ9$GD-dimer:ŗ;ǭūĦĻJƱȄ)G.A9ŞƝ5G 6ǙEH4Gɏ7779ɐŢƯƺ94¥Ɲ'.D-dimer;ƒijXa¸ơŹƎ ż(Latex turbidimetric immunoassay)5F%H;ŁrlD- dimerŁ£JƝ4 G?.—æ¥Ɲ'.rlƝ D-dimer ƈąȃǫ ÎƑů£6Õı'ąȧƨȂ¨

Øǝ5G%6 ÄŘ'4FǤĞƨ8ŞƝIJBƱȄ&H4Gɏ71ɐįĽ¼:

D-dimer5öÍ³Þ @6AEH.B::ŞĶ8ùÏ5;81.,:Óç6'4

įĽ¼94¿êçĀ ſIJÏ'ĭƚuNv„ˆE:D-dimer:öÍ;ƛ(GB ::3w6şȯ5;ØǶÏ5!G>7:ǭūĦĻ9;Ǧ1481.B:6Ǚ EHG

?.—æįĽǭ:AT5;ÉƍĨ7:śƐ94BŞĶ8ùÏ;ȄAEH8 1.ŢƯƺ5:ATſIJ;†‹lMibOżJƝ4ƑȈ:ſIJJƈą'4 G.AƓ:ů£94BATſIJJƈą)G%6 Øǝ5FÎƑ5:”ĖIJ BȁŘ&H4Gɏ72ɐ

—æŢƯƺ5;ŞĶĖ;ȄAEH81. įĽǭ941wD= 2w9

4D-dimer­:ŗ³Þ6 AT:¢Ž³Þ Ƴ&H.%:ƙƞ6'4įĽ¼

:1ǭ9DGǭūIJ:“șɏB'#;ǭūĦĻ³Þɕthrombogenisityɐ:njŨ9DF ÂǹƜƑ5GD-dimer öÍ'?.,H9Ÿ¿êçĀ5GAT Ɓȇ'.nj Ũ5G6ǙEHG

APTT;¼çDž¿êNjȋD=»ȕNjȋ9$GçĀſIJJÕŚ.A9aX„‹

oˆYůũ5ƝEHGɏ1519ɐŢƯƺ5;įĽǭ:APTT ÔǙ­ǂè¼5

;GB::1w9ŞĶ8ĠȬJƳ',H 3w?5ǐŇ&H.?.ɑ%:njŨ;

T-TAS94¿êçĀŵǝJȂ¨)GARhiw:OTƭǕ:ǎśƨùÏ6Œǧ'4

.D14APTT:ĠȬ;įĽ¼94¿êçĀŵǝ ſIJÏ)G%65¿

êçĀ Ɓȇ&H.%69Ȋç)GB:6Ǚ.''ĠȬ'4.APTT:­;

77

*HBÔǙ­:ǂè¼5:ùÏ51..AÁǭ³Þ9?5Ȳ14.ǿ5;8

%6Äő'.ŒŒPT;ɑƯƺşȯJȕ'4ŞĶ8ùÏ;ȄAEH81.

ȓ'.ÛƸ¿êDž:Ɂƪ;¿êUaZ‹mº£:ŒȡÂ9$GÕı 7:Ʒğ ƛ(4GJȂ¨)G.A9;ŞƝ5G6ǙEHGɏ1519ɐ''%HE :Ȃ¨;ȃɊǁ¼5:ÕıJ28"ÜI+.B:9)"8Ćȳ:ƛ£ÕıŽ5:

Ŷǭ6Áǭ;û#:»ȕçĀ9DFÈĬ&HǭūĦĻɏǭďŦſIJ6¿êçĀſIJɐ 6ǓƊDžE8GDzȸ8Õı5G%:%6 ĪŤE:¿êDžůũ5;ǭūĦĻ :€of„ˆYJȺ'#'4!.dzç5G6ǙEHGȒĝROTEM C T-TAS 87:ºǭJÆƝ)G¿êDžůũ žƪ&H4Gɏ2022, 29, 80ɐT-TAS5;

ƀȖJùÏ&+8 EŁ¿êÀƙ'.ºǭJųōǭǁ5G|OX‡ƀȋ9ƀ)%6 5ƀȋ¼:\ƒ‹[ˆCNJǖçĀ ů£:ŒȡJſIJÏ',H ģ!Ȩ68Fƛ£

¼5Ȋ%Gƛƙƨ8ǭūĦĻJģ!Ȋ%)%6 Øǝ8ŵå5G,:.A—?5 Ȃ¨5!81.ǭūĦĻǝ:Ȃ¨ T-TASůũ5;Ȃ¨5!GB:6ǙEH4 Gɏ2022ɐ

1ǭ87ǭƀȖğ țȡ¡94ȉǭƘRajƒ‹c9DGƽçĀƾ:¿

êçĀ:ſIJ ģ!Ȋ%&HG%6 ƬEH4GŢƯƺ5;įĽǭ94 ARhiw:OT ÉƍÊ6ŹȎ'4ɓw6ŖşEŞĶ8ƆĐJƳ',H 3w?5ǐŇ&H.%H;Af:Ʀƛ9DFįĽ¼9$GǭƂ:1Ƌ ƛ(.

njŨ¿êçĀ:ſIJ ƛ(.%6 ǙEH.ŒŒPLhiw:OT5;3w9 4:@ŞĶ8ƆĐ @EH.%:njŨEAf ŇǏ)G%65įĽ¼:¼Ʃȴ Ĉ ƛ(ȼÁ'.\ƒ‹[ˆ6uSˆ‰N†vƒˆmçĀɏvWFɐ: ē9DF ǭďŦŵǝ:ſIJ9DGǭūĦĻǝ:“ș ǐŇ&HGB:6Ǚ.?.ŢƯƺ5

;įĽǭ:Ŋǭ;ÙįĽ¼EĆœ'. %H;ĕįĽ:y‹_ˆY„‹m:

uiX9DGljǜȴĈ9Ȋç)GǭūĦĻ:ħɀJ8#).A?.Ŋǭ:'ř&87 JǙĺ'.njŨ5G %:%6;ĕįǛy‹_ˆY514B,:Éƍ Ùį Ľ?5žĎ'ÙįĽ94BǭƂ¿ê:“ș ƛ(G6%6JŘE9'.

78 ļ ƬGȱF%H?5AfƦƗś:įĽ¼6šŮȡ¡9$GǭƂIJƔ:ùÏJ ŹȎ'.óà;ȄAEH48—æįĽ¼94:@Ìƨ8ǭƂIJƔ:ùÏ Ǹċ&H. šŮȡ¡5;*H:ůũɁƪ94BŞĶ8ǎśƨùÏ;ȄAEH 81.%:ƙƞ6'4šŮȡ¡5;įĽ6ŹȎ'4ǭƂ:ƃ@ Đ8%6C ljÎ6Ƒƙƨ8Éƍ9DGǭǁ¼ƩȴĈ Đ8%687 Ōƈ&HGįĽ¼5

;ǭƂ:1Ƌ9DFȉǭƘRajƒ‹c9DGƽçĀ:ſIJÏ ƛ(G ǭ ƀȖğ ȖšŮǭǁ¼5;,H ģ!Ȋ%&H81.6ǙEH.?.šŮ ǭǁ¼5;¼ƩȴĈ9DG\ƒ‹[ˆ:ȼÁ Ȋ%F9#.AǭďŦ¿ȶBĵȊ&

H86ǙEH..6¼ƩȴĈ āì'vWF ǭǁú:\ƒ‹[ˆ6njÜ' .6'4BÎǞ6ŹȎ'ƀH ǔC8Ɣĸ5G.AvWF: ē;Ȋ!9##

vWFJ˜'.ǭďŦ:ſIJÏBĵȊ&H9#6ǙEHG?.ǭǁ¼Ʃljǜ ȴĈ&H48ƔŻ5H<¼Ʃljǜ9āì)Gl‡ˆz€`‚„ˆCw‡jOˆ

Cƾ:ŁǭūſIJƑȈ9DFſIJÏ&H.¿êçĀ;ȖC9ſÏ&HG6ǙE H.

–Ðƥ5;ɋǭëijǚCǭǁȴĈJŞ)GƢijijǚ9$GAfś:ǭūĦĻ„a X;öü)Gɏ70, 81, 82ɐ?.Ɠ:Af:òƲƢij5GµĚġȭȫºƤCŅĤï įƿƤ:ǤЦDFBɑòƲ68GįĽ:ƣƙĂƨùÏ ȍğ5G6ǙEHG—

æ:€k…5;±ę2 Ÿ Ÿ6ǩɍ:«£J¥Ɲ'..AɋǭëƤCǭ ǁȴĈBȄAEH*ŘE8ǭūĦĻ9;ǦE81.6ǙEHG

š:njŨE–:AfƔĸ5BÝű9šŮǭ5:¿êƠę ȄAEH8ôÜ 5BįĽ¼5:¿ê“șƔĸ9Ȳ14GØǝIJ ĥ#Ƴã&HG

79

ドキュメント内 高頻度心房刺激犬を用いた血液凝固能と抗血栓治療に関する研究 (ページ 78-101)